The European Investment Bank and Angelini Ventures announced a €150 million investment vehicle targeting seven to ten European health startups across biotech, medtech and digital health. The program aims to strengthen continental scale‑ups and close financing gaps that have hindered innovation growth in Europe. The fund will support later‑stage rounds and follow‑on capital while prioritizing technologies with commercial and manufacturing potential. Officials framed the move as part of a broader strategy to attract industry investment and retain R&D activity in Europe. Market participants expect the partnership to catalyze regional consolidation, spur cross‑border M&A and provide growth capital for firms seeking to scale clinical and manufacturing operations.